Literature DB >> 20088374

[Prospects of antisense therapy technologies].

M Iu Skoblov.   

Abstract

Up-to now three variants of antisense technologies are known, namely antisense oligonucleotides, RNA interference, and ribozymes. In spite of different mechanisms of action, all of them are united by the common principle: an antisense preparation works after binding with RNA-target by forming a duplex. Today all three variants are intensively used in vivo. Present posture of affairs in use of antisense technologies for treating various diseases is considered in the review.

Mesh:

Substances:

Year:  2009        PMID: 20088374

Source DB:  PubMed          Journal:  Mol Biol (Mosk)        ISSN: 0026-8984


  2 in total

1.  Inhibition of γ/β Globin Gene Switching in CD 34+ Derived Erythroid Cells by BCL11A RNA Silencing.

Authors:  Seyyed Asadallah Taghavi; Kamran Mousavi Hosseini; Gholamhossein Tamaddon; Leila Kasraian
Journal:  Indian J Hematol Blood Transfus       Date:  2019-05-13       Impact factor: 0.900

2.  Synthesis and application of stationary phase for DNA-affinity chromatographic analysis of unmodified and antisense oligonucleotide.

Authors:  Sylwia Studzińska; Ewelina Zawadzka; Szymon Bocian; Michał Szumski
Journal:  Anal Bioanal Chem       Date:  2021-06-24       Impact factor: 4.142

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.